RESUMEN
Introduction: The presence of a fragility fracture increases the risk of new fractures. The timely and prompt initiation of treatment for osteoporosis can reduce the incidence of new fractures, for which adherence to management is a determining factor. The main objective of the study was to characterize the secondary prevention program for fragility hip fractures in patients older than 65 years, determine adherence to treatment and its effect on the appearance of new fractures in the established follow-up period. Materials and Methods: A descriptive retrospective cohort study was carried out. Patients older than 65 years with a fragility hip fracture treated by an Orthogeriatric Clinical Care Center between May 2014 and April 2020 who completed a one-year follow-up were included. Results: A final sample of 290 patients was obtained (226 women and 64 men) with an average age of 82.27 years. It was found that 84.5% of patients received indications to start osteoporotic management prior to hospital discharge and only 35.2% started the treatment in the first 6 postoperative months. 16.6% (n = 48) of patients presented a new fracture, with no significant difference between those who started their osteoporosis treatment in a timely manner. Out of the 48 patients, 5 patients (10.4%) met therapeutic failure criteria. Discussion: Most patients (84.5%) received indications for starting osteoporotic treatment before hospital discharge, nevertheless 35.2% started it during the first 6 postoperative months. 16.6% of patients presented a new fracture during follow up, of which only five met therapeutic failure criteria. Conclusions: No significant differences were found between the presence of new fractures and early initiation of osteoporotic management. However, literature shows that prompt and timely osteoporotic treatment reduces the incidence of new fractures, thus measures must be implemented to strengthen the adherence and surveillance of patients to the indicated treatment.
RESUMEN
La insuficiencia cardíaca congestiva es un síndrome caracterizado por reducción del gasto cardíaco, aumento de las presiones de llenado ventricular y activación neuroendocrina, que lleva a un proceso de fibrosis y apoptosis de la célula cardíaca. Afecta alrededor de 23 millones de personas en el mundo y confiere un pésimo pronóstico una vez se diagnostica. Desde el punto de vista fisiopatológico, la relación entre citocinas pro-inflamatorias, activación neuro-hormonal y alteraciones gastrointestinales conduce a un estado denominado caquexia cardíaca, determinado por pérdida acelerada de peso, fatiga, reducción de la fuerza muscular, anorexia y disminución de la calidad de vida; este proceso es capaz de deteriorar aún más el pronóstico vital de estos pacientes. En las últimas dos décadas, se han realizado avances en el tratamiento farmacológico y eléctrico de la falla cardíaca; sin embargo los estudios en el campo no farmacológico son pocos, en especial en el aspecto nutricional, y así mismo son escasas las recomendaciones de las guías internacionales acerca del tema. En estudios pequeños, una aproximación nutricional ha demostrado impactar de manera positiva la calidad de vida y tolerancia al ejercicio, si bien se requieren grandes estudios para determinar la viabilidad de este abordaje en pacientes con falla cardíaca.
Congestive heart failure is a syndrome characterized by reduced cardiac output, increased ventricular filling pressures and neuroendocrine activation, which leads to a process of cardiac cell fibrosis and apoptosis. It affects nearly 23 million people worldwide and once diagnosed has a poor prognosis. From a physiopathological point of view, the relationship between pro-inflammatory cytokines, neurohormonal activation and gastrointestinal disturbances leads to a condition called cardiac cachexia, characterized by accelerated weight loss, fatigue, decreased muscle strength, anorexia and decreased quality of life. This process can further deteriorate life prognosis of these patients. In the past two decades many advances regarding the pharmacological and electrical treatment of heart failure have been made, but studies in the non-pharmacological field are few, especially in the nutritional aspect, and likewise, the recommendations of the international guidelines on the subject are scarce. In small studies, a nutritional approach has shown to positively impact the quality of life and exercise tolerance, although larger studies are needed to determine the feasibility of this approach in patients with heart failure.